Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Advances in Gastroenterology and Oncology Research
This week's episode covers groundbreaking research in gastric cancer treatment, updated IBD guidelines, microbiome advances, and the impact of stress on gastrointestinal health. Our hosts discuss key findings from recent studies and their clinical implications.
Bibliography
1. Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial.
Authors: Yan C, Yang Z, Shi Z, et al.
Journal: JAMA oncology, 2026 Jul 1
PMID: 42166134
DOI: 10.1001/jamaoncol.2026.1347
2. Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.
Authors: Ooi CJ, Ling KL, Limsrivilai J, et al.
Journal: Journal of gastroenterology and hepatology, 2026 Jul
PMID: 42117726
DOI: 10.1111/jgh.70379
3. Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.
Authors: Constantine-Cooke N, Gros B, Plevris N, et al.
Journal: Gut, 2026 Jul 8
PMID: 41554630
DOI: 10.1136/gutjnl-2025-337846
4. The hallmarks of pancreatic cancer.
Authors: Kane LE, Hackett D, Lyons R, et al.
Journal: Cancer letters, 2026 Jul 10
PMID: 41856311
DOI: 10.1016/j.canlet.2026.218437
5. Bifidobacteria and Their Health-Promoting Effects.
Authors: Hidalgo-Cantabrana C, Delgado S, Ruiz L, et al.
Journal: Microbiology spectrum, 2017 Jun
PMID: 28643627
DOI: 10.1128/microbiolspec.BAD-0010-2016
6. C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.
Authors: Jaspers YRJ, Dijkstra IME, Engelen M, et al.
Journal: Pharmacology & therapeutics, 2026 Sep
PMID: 42320861
DOI: 10.1016/j.pharmthera.2026.109070
7. A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor-Associated Ketoacidosis Case Reports.
Authors: Snel LIP, Li X, Jamaludin F, et al.
Journal: Acta anaesthesiologica Scandinavica, 2026 Jul
PMID: 42130079
DOI: 10.1111/aas.70254
8. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
Authors: Konturek PC, Brzozowski T, Konturek SJ
Journal: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011 Dec
PMID: 22314561
9. Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.
Authors: Nardone OM, Calabrese G, Ford AC, et al.
Journal: Inflammatory bowel diseases, 2026 Jul 1
PMID: 41784159
DOI: 10.1093/ibd/izag022
10. A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.
Authors: Kim SG, Kim TO, Jung SW, et al.
Journal: Gut and liver, 2026 Jul 15
PMID: 42325011
DOI: 10.5009/gnl260057
Authors: Yan C, Yang Z, Shi Z, et al.
Journal: JAMA oncology, 2026 Jul 1
PMID: 42166134
DOI: 10.1001/jamaoncol.2026.1347
2. Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.
Authors: Ooi CJ, Ling KL, Limsrivilai J, et al.
Journal: Journal of gastroenterology and hepatology, 2026 Jul
PMID: 42117726
DOI: 10.1111/jgh.70379
3. Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.
Authors: Constantine-Cooke N, Gros B, Plevris N, et al.
Journal: Gut, 2026 Jul 8
PMID: 41554630
DOI: 10.1136/gutjnl-2025-337846
4. The hallmarks of pancreatic cancer.
Authors: Kane LE, Hackett D, Lyons R, et al.
Journal: Cancer letters, 2026 Jul 10
PMID: 41856311
DOI: 10.1016/j.canlet.2026.218437
5. Bifidobacteria and Their Health-Promoting Effects.
Authors: Hidalgo-Cantabrana C, Delgado S, Ruiz L, et al.
Journal: Microbiology spectrum, 2017 Jun
PMID: 28643627
DOI: 10.1128/microbiolspec.BAD-0010-2016
6. C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.
Authors: Jaspers YRJ, Dijkstra IME, Engelen M, et al.
Journal: Pharmacology & therapeutics, 2026 Sep
PMID: 42320861
DOI: 10.1016/j.pharmthera.2026.109070
7. A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor-Associated Ketoacidosis Case Reports.
Authors: Snel LIP, Li X, Jamaludin F, et al.
Journal: Acta anaesthesiologica Scandinavica, 2026 Jul
PMID: 42130079
DOI: 10.1111/aas.70254
8. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
Authors: Konturek PC, Brzozowski T, Konturek SJ
Journal: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011 Dec
PMID: 22314561
9. Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.
Authors: Nardone OM, Calabrese G, Ford AC, et al.
Journal: Inflammatory bowel diseases, 2026 Jul 1
PMID: 41784159
DOI: 10.1093/ibd/izag022
10. A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.
Authors: Kim SG, Kim TO, Jung SW, et al.
Journal: Gut and liver, 2026 Jul 15
PMID: 42325011
DOI: 10.5009/gnl260057
